Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp

M A Pfaller; D J Diekema; G W Procop; M G Rinaldi

doi:10.1128/JCM.00403-07

Back

Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp

Journal article

Open access

Peer reviewed

Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp

M A Pfaller, D J Diekema, G W Procop and M G Rinaldi

Journal of clinical microbiology, Vol.45(11), pp.3522-3528

11/2007

DOI: 10.1128/JCM.00403-07

PMCID: PMC2168477

PMID: 17913927

Files and links (1)

url

https://doi.org/10.1128/JCM.00403-07View

Published (Version of record) Open Access

Abstract

A fully automated commercial antifungal susceptibility test system (VITEK 2; bioMérieux, Inc., Hazelwood, MO) was compared in three different laboratories with the Clinical and Laboratory Standards Institute (formerly the NCCLS) reference broth microdilution method (BMD) by testing 2 quality control strains, 10 reproducibility strains, and 426 isolates of Candida spp. against amphotericin B, flucytosine, and voriconazole. Reference BMD MIC endpoints were established after 24 and 48 h of incubation. VITEK 2 system MIC endpoints were determined spectrophotometrically after 9.1 to 27.1 h of incubation (mean, 12 to 14 h). Excellent essential agreement (within 2 dilutions) between the VITEK 2 system and the 24- and 48-h BMD MICs was observed for all three antifungal agents: amphotericin B, 99.1% and 97%, respectively; flucytosine, 99.1% and 98.8%, respectively; and voriconazole, 96.7% and 96%, respectively. Both intra- and interlaboratory agreements were >98% for all three drugs. The overall categorical agreements between the VITEK 2 system and BMD for flucytosine and voriconazole were 98.1 to 98.6% at the 24-h BMD time point and 96.9 to 97.4% at the 48-h BMD time point. The VITEK 2 system reliably detected flucytosine and voriconazole resistance among Candida spp. and demonstrated excellent quantitative and qualitative agreement with the reference BMD method.

Antifungal Agents - pharmacology

Triazoles - pharmacology

Reference Standards

Time Factors

Culture Media

Humans

Amphotericin B - pharmacology

Voriconazole

Candida - drug effects

Flucytosine - pharmacology

Pyrimidines - pharmacology

Microbial Sensitivity Tests - methods

Details

Title: Subtitle: Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp
Creators: M A Pfaller - Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
D J Diekema
G W Procop
M G Rinaldi
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.45(11), pp.3522-3528
DOI: 10.1128/JCM.00403-07
PMID: 17913927
PMCID: PMC2168477
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 11/2007
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986372202771

Metrics

25 Record Views

113 Times Cited - Web of Science